ERapa restores a normal life span in a FAP mouse model

Cancer Prevention Research

Volumn 7, Issue 1, 2014, Pages 169-178

  Hasty, Paul ^a,b   Livi, Carolina B ^a,b,d   Dodds, Sherry G ^a   Jones, Diane ^a   Strong, Randy ^a,b   Javors, Martin ^a   Fischer, Kathleen E ^a,b   Sloane, Lauren ^b,c   Murthy, Kruthi ^a   Hubbard, Gene ^a,b   Sun, Lishi ^a   Hurez, Vincent ^a   Curiel, Tyler J ^a,b   Sharp, Zelton Dave ^a,b  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SUNY Delhi   (United States)

^d AGILENT TECHNOLOGIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER PREVENTION; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TARGETING; DRUG TISSUE LEVEL; FAMILIAL COLON POLYPOSIS; FEMALE; HEMATOCRIT; IMMUNE DEFICIENCY; IMMUNE SYSTEM; INFECTION; LIFESPAN; LONG TERM CARE; MICROENCAPSULATION; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SMALL INTESTINE; SUPPRESSOR CELL; TOXOPLASMOSIS; TUMOR MODEL; WILD TYPE;

ADENOMATOUS POLYPOSIS COLI; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENES, APC; INTESTINES; LONGEVITY; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MULTIPROTEIN COMPLEXES; NEOPLASM TRANSPLANTATION; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84892421283     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0299     Document Type: Article

References (50)

1. Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection from colorectal cancer after colonoscopy: a populationbased, case-control study. Ann Inter Med 2011;154: 22-30.
2. Wallace MH, Phillips RK. Upper gastrointestinal disease in patients with familial adenomatous polyposis. Br J Surg 1998;85: 742-50.
3. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149: 274-93.
4. Hasty P. Rapamycin: the cure for all that ails. J Mol Cell Biol 2010;2: 17-9.
5. Piselli P, Serraino D, Segoloni GP, Sandrini S, Piredda GB, Scolari MP, et al. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. Eur J Cancer 2013;49: 336-44.
6. Livi CB, Hardman RL, Christy BA, Dodds SG, Jones D, Williams C, et al. Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors. Aging (Albany NY). 2013;5: 100-10.
7. Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, et al. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging (Albany NY). 2012; 4: 709-14.
8. Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcD716 mice. Proc Natl Acad Sci U S A 2008;105: 13544-9.
9. Koehl GE, Spitzner M, Ousingsawat J, Schreiber R, Geissler EK, Kunzelmann K. Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APCMin/+mice. Oncogene 2010;29: 1553-60.
10. Wijnhoven SW, Beems RB, Roodbergen M, van den Berg J, Lohman PH, DiderichK, et al. Accelerated aging pathology in ad libitum fed Xpd (TTD) mice is accompanied by features suggestive of caloric restriction. DNA Repair (Amst) 2005;4: 1314-24.
11. Yuan R, Tsaih SW, Petkova SB, Marin de Evsikova C, Xing S, Marion MA, et al. Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell 2009;8: 277-87.
12. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009;460: 392-5.
13. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2011; 66: 191-201.
14. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, et al. Rapamycin slows aging in mice. Aging Cell 2012;11: 675-82.
15. Sharp ZD, Lee WH, Nikitin AY, Flesken-Nikitin A, Ikeno Y, Reddick R, et al. Minimal effects of dietary restriction on neuroendocrine carcinogenesis in Rb+/- mice. Carcinogenesis 2003;24: 179-83.
16. Zhang Y, Bokov A, Gelfond J, Soto V, Ikeno Y, Hubbard G, et al. Rapamycin extends life and health in C57BL/6 mice. J Gerontol A Biol Sci Med Sci 2013 May 16. [Epub ahead of print].
17. Hurez V, Daniel BJ, Sun L, Liu AJ, Ludwig SM, Kious MJ, et al. Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Res 2012;72: 2089-99.
18. Wei S, Marches F, Borvak J, Zou W, Channon J, White M, et al. Toxoplasma gondii-infected human myeloid dendritic cells induce Tlymphocyte dysfunction and contact-dependent apoptosis. Infect Immun 2002;70: 1750-60.
19. Wei S, Marches F, Daniel B, Sonda S, Heidenreich K, Curiel T. Pyridinylimidazole p38 mitogen-activated protein kinase inhibitors block intracellular Toxoplasma gondii replication. Int J Parasitol 2002;32: 969-77.
20. Daniel BJ, Pandeswara S, Brumlik MJ, Liu A, Thibodeaux SR, Ludwig SM, et al. A simple method to detect Toxoplasma gondii-specific cytotoxic T cells in vivo. J Immunol Methods 2010;355: 86-90.
21. Sanchez-Fueyo A, Sandner S, Habicht A, Mariat C, Kenny J, Degauque N, et al. Specificity of CD4+CD25+ regulatory T cell function in alloimmunity. J Immunol. 2006;176: 329-34.
22. Khan MZ, Prebeg Z, Kurjakovic N. A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. I. Manipulation of drug release using Eudragit L100-55 and Eudragit S100 combinations. J Control Release 1999;58: 215-22.
23. Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 2012;441: 1-21.
24. Meyuhas O, Dreazen A. Ribosomal protein S6 kinase from TOP mRNAs to cell size. Prog Mol Biol Transl Sci 2009;90: 109-53.
25. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012;485: 109-13.
26. Trepanier DJ, Gallant H, Legatt DF, Yatscoff RW. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clin Biochem 1998;31: 345-51.
27. Chauvin C, Koka V, Nouschi A, Mieulet V, Hoareau-Aveilla C, Dreazen A, et al. Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene 2013 Jan 14. [Epub ahead of print].
28. Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M, et al. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res 2012;72: 6468-76.
29. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression ofmRNAtranslation. Proc Natl Acad SciUSA 2008;105: 17414-9.
30. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, RuggeroD, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009;7:e1000038.
31. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATPcompetitive mammalian target of rapamycin inhibitor reveals rapamycin- resistant functions of mTORC1. J Biol Chem 2009;284: 8023-32.
32. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66: 1500-8.
33. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101.
34. Efeyan A, Sabatini DM.mTORand cancer: many loops in one pathway. Curr Opin Cell Biol 2010;22: 169-76.
35. Russell ES, Neufeld EF, Higgins CT. Comparison of normal blood picture of young adults from 18 inbred strains of mice. Proc Soc Exp Biol Med 1951;78: 761-6.
36. Lamming DW, Ye L, Astle MC, Baur JA, Sabatini DM, Harrison DE. Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive. Aging Cell 2013;12: 712-8.
37. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012;335: 1638-43.
38. Neff F, Flores-Dominguez D, Ryan DP, Horsch M, Schroder S, Adler T, et al. Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest 2013;123: 3272-91.
39. Richardson A. Rapamycin, anti-aging, and avoiding the fate of Tithonus. J Clin Invest 2013;123: 3204-6.
40. Marone R, Erhart D, Mertz AC, Bohnacker T, Schnell C, Cmiljanovic V, et al. Targeting melanoma with dual phosphoinositide 3-kinase/ mammalian target of rapamycin inhibitors. Mol Cancer Res 2009; 7: 601-13.
41. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, BachmannMF, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460: 108-12.
42. Ferrer IR, Wagener ME, Robertson JM, Turner AP, Araki K, Ahmed R, et al. Cutting edge: rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J Immunol 2010;185: 2004-8.
43. Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379: 1591-601.
44. Strong R, Miller R, Astle C, Floyd R, Flurkey K, Hensley K, et al. Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell 2008;7: 641-50.
45. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991;115: 952-4.
46. Steinbach G, Lynch PM, Phillips RK, Wallace MH,Hawk E, GordonGB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342: 1946-52.
47. Yilmaz OH, Katajisto P, Lamming DW, Gultekin Y, Bauer-Rowe KE, Sengupta S, et al. mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature 2012;486: 490-5.
48. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009;457: 608-11.
49. Ma WW, Hidalgo M. Exploiting novel molecular targets in gastrointestinal cancers. World J Gastroenterol 2007;13:5845.
50. Soefje SA, Karnad A, Brenner AJ. Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol 2011;6: 125-9.